Curium | Jotup

Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Retrieved on:

Tuesday, April 9, 2024

Curium, Civil service commission, Prostate cancer, Patient, PET, News, INN, Cancer, Prostate, European, European Commission, FDA, Nuclear medicine, Physician, PSMA, Food, Medical imaging

PARIS, April 09, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in the Netherlands the first commercial dose of PYLCLARI® has been sold.

Key Points:

PARIS, April 09, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in the Netherlands the first commercial dose of PYLCLARI® has been sold.
In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021.
It is the #1 utilized PSMA PET agent in the U.S. market.
The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018.

Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.

Retrieved on:

Monday, March 25, 2024

Curium, FMI, Novartis, Eli Lilly, Face, FAP, Associate, Hospital, Bayer, Cancer, Actinium-225, Medicare, Radiopharmaceutical, Radio, Therapy, Eli Lilly and Company, Government

NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide. With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade. Rising incidences of cancer and cancer-associated diseases are one of the main reasons for that.

Key Points:

This report by FMI dives deep into why this market is thriving, what bumps it might face, and the exciting possibilities ahead.
NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide.
With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade.
Although the market is still in its nascent stages, it is slated to pick up some pace in the coming decade.

Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Retrieved on:

Thursday, March 7, 2024

Curium, European Commission, Physician, FDA, Food, PSMA, Prostate, INN, European, Civil service commission, Patient, Nuclear medicine, PET, Cancer, Prostate cancer, Medical imaging

PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy.

Key Points:

PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy.
Today’s announcement follows the decision in July 2023 by the European Commission granting marketing authorization for PYLCLARI® in the European Union.
On 3rd February 2024 The Italian Medicines Agency (Agenzia Italiana del Farmaco) published the decision for PYLCLARI® in Italy.
The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018.

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on:

Tuesday, February 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points:

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on:

Tuesday, February 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points:

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

Retrieved on:

Monday, January 22, 2024

Curium, Prostate cancer, Receptor (biochemistry), Nuclear medicine, GMP, USD, News, Diagnosis, Pharmaceutical industry

USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.

Key Points:

USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.
COPENHAGEN, Jan. 22, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") – (TICKER: CURAS) today announced the achievement of the first milestone under the agreement with Curium inc., to develop Curasight's uTRACE® PET imaging technology for the improved diagnosis of prostate cancer.
The milestone relates to the validation of GMP manufacturing of finished product.
The USD 500.000 milestone is the first in the agreement signed with Curium Inc. in May 2023.
Curasight is eligible to receive up to mUSD 70 in development and commercial milestones as well as double-digit percentage royalties on sales in major markets upon eventual commercialization.

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

Retrieved on:

Monday, January 22, 2024

Curium, Prostate cancer, Receptor (biochemistry), Nuclear medicine, GMP, USD, News, Diagnosis, Pharmaceutical industry

USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.

Key Points:

USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.
COPENHAGEN, Jan. 22, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") – (TICKER: CURAS) today announced the achievement of the first milestone under the agreement with Curium inc., to develop Curasight's uTRACE® PET imaging technology for the improved diagnosis of prostate cancer.
The milestone relates to the validation of GMP manufacturing of finished product.
The USD 500.000 milestone is the first in the agreement signed with Curium Inc. in May 2023.
Curasight is eligible to receive up to mUSD 70 in development and commercial milestones as well as double-digit percentage royalties on sales in major markets upon eventual commercialization.

Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule

Retrieved on:

Thursday, November 23, 2023

Curium, Oncology, Physician, Master of Science, Nuclear medicine, Prostate cancer, MD, Patient, Safety, Urology, Radiation, Pharmaceutical industry

ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.

Key Points:

ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.
ECLIPSE is a Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer.
The ECLIPSE trial enrolled over 400 patients, ahead of schedule, across 51 trial sites in the United States and Europe.
Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium said: “We are proud to announce the completion of enrollment in the ECLIPSE trial, and would like to thank the patients, trial investigators, clinical research partners and our Curium cross-functional teams for their dedication and commitment.

Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer

Retrieved on:

Thursday, November 16, 2023

Curium, European Commission, INN, Laboratory, Civil service commission, Patient, Nuclear medicine, European, Prostate cancer, PSMA, Cancer, Partnership, PET, Physician, Medical imaging

As a world leader in nuclear medicine, Curium is pleased to be improving the choice of diagnostic tools available to physicians in Greece to diagnose prostate cancer – ultimately for the benefit of prostate cancer patients.”

Key Points:

As a world leader in nuclear medicine, Curium is pleased to be improving the choice of diagnostic tools available to physicians in Greece to diagnose prostate cancer – ultimately for the benefit of prostate cancer patients.”
Savvas Thalasselis, Managing Director, SYN Innovation Laboratories SA commented: “Today’s announcement of the first dose of PYLCLARI® in Greece is an important milestone for the detection of prostate cancer, in particular for the primary staging of patients with high-risk prostate cancer prior to initial curative therapy.
Our long-term partnership with Curium has demonstrated our commitment to diagnosing patients with cancer, and we look forward to further supporting Curium with their future pipeline of diagnostic and therapeutic products.”
Today’s announcement follows the decision in July 2023 by the European Commission granting marketing authorization for PYLCLARI® in the European Union.
SYN Innovation Laboratories has been a partner with Curium since 2017, with exclusive manufacturing and distribution rights for Curium’s wide range of positron emission tomography products in Greece.
SYN Innovation Laboratories will manufacture PYLCLARI® at its facilities in Athens, Greece.

SHINE Technologies Names Harrie Buurlage Chief Commercial Officer of Isotopes

Retrieved on:

Monday, September 11, 2023

JANESVILLE, Wis., Sept. 11, 2023 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company, today announced that Harrie Buurlage has been named Chief Commercial Officer of Isotopes. Buurlage, who has been the General Manager of SHINE Europe since 2019, will now oversee all commercial aspects of SHINE's therapeutic and diagnostic medical isotope divisions. Supporting Buurlage in driving the growth of SHINE's medical isotope business will be Magdalena Brzezowska, a proven leader with extensive commercial experience in radiopharmaceuticals, who has been named Vice President of Sales and Business Development.

Key Points:

JANESVILLE, Wis., Sept. 11, 2023 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company, today announced that Harrie Buurlage has been named Chief Commercial Officer of Isotopes.
Buurlage, who has been the General Manager of SHINE Europe since 2019, will now oversee all commercial aspects of SHINE's therapeutic and diagnostic medical isotope divisions.
He was the Chief Operating Officer at NRG in the Netherlands, overseeing key nuclear installations, and the global director for nuclear manufacturing at Covidien USA, now Curium Pharma.
"SHINE is well-positioned to provide increased access to life-saving medicine, and I look forward to helping usher in the next era of medical isotope production," Buurlage said.